Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Gross Margin (2016 - 2026)

Anika Therapeutics has reported Gross Margin over the past 17 years, most recently at 64.15% for Q1 2026.

  • Quarterly Gross Margin rose 805.0% to 64.15% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 58.59% through Mar 2026, down 266.0% year-over-year, with the annual reading at 56.56% for FY2025, 682.0% down from the prior year.
  • Gross Margin was 64.15% for Q1 2026 at Anika Therapeutics, up from 62.65% in the prior quarter.
  • Over five years, Gross Margin peaked at 66.69% in Q2 2024 and troughed at 199.14% in Q4 2023.
  • The 5-year median for Gross Margin is 60.16% (2023), against an average of 33.73%.
  • Year-over-year, Gross Margin plummeted -18607bps in 2022 and then surged 25510bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 135.45% in 2022, then plummeted by -47bps to 199.14% in 2023, then skyrocketed by 128bps to 55.96% in 2024, then rose by 12bps to 62.65% in 2025, then increased by 2bps to 64.15% in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Gross Margin are 64.15% (Q1 2026), 62.65% (Q4 2025), and 56.02% (Q3 2025).